Cadazolid for the treatment of Clostridium difficile

Expert Opinion on Investigational Drugs

Volumn 26, Issue 4, 2017, Pages 509-514

  Endres, Bradley T ^a   Bassères, Eugénie ^a   Alam, M Jahangir ^a   Garey, Kevin W ^a  

^a UNIVERSITY OF HOUSTON   (United States)

Author keywords

anaerobic infections; Antibiotic; cadazolid; Clostridium difficile; diarrhea; vancomycin

Indexed keywords

CADAZOLID; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; CB-183,315; CYCLOPEPTIDE; FIDAXOMICIN; LIPOPEPTIDE; OXAZOLIDINONE DERIVATIVE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONFUSION; DIZZINESS; DRUG ABSORPTION; DRUG EFFICACY; DRUG FECES LEVEL; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; DYSPEPSIA; HEADACHE; HOST; HUMAN; MEDICINAL CHEMISTRY; MICROFLORA; MULTICENTER STUDY (TOPIC); PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); CLOSTRIDIUM INFECTIONS; COMPARATIVE STUDY; DRUG EFFECTS; MICROBIOLOGY; PEPTOCLOSTRIDIUM DIFFICILE; TREATMENT OUTCOME;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; HUMANS; LIPOPEPTIDES; OXAZOLIDINONES; PEPTIDES, CYCLIC; TREATMENT OUTCOME;

EID: 85016146767     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1080/13543784.2017.1304538     Document Type: Article

References (40)

1. Hall AJ, Curns AT, McDonald LC, et al. The roles of Clostridium difficile and norovirus among gastroenteritis-associated deaths in the United States, 1999–2007. Clin Infect Dis. 2012 Apr 4;55:216–223.• Reports on CDI being the most common cause of death due to gastroenteritis in the USA.
2. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005 Dec 8;353(23):2433–2441.
3. Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015 Feb 26;372(9):825–834.
4. Sun X, Savidge T, Feng H., The enterotoxicity of Clostridium difficile toxins. Toxins (Basel). 2010 Jul;2(7):1848–1880.
5. Darkoh C, Turnwald BP, Koo HL, et al. Colonic immunopathogenesis of Clostridium difficile infections. Clin Vaccine Immunol. 2014 Apr;21(4):509–517.
6. Dupont HL, Garey KW. Clostridium difficile infection:an emerging epidemic with more questions than answers. Future Microbiol. 2010 Aug;5(8):1153–1156.
7. Garey KW, Jiang Z-D, Ghantoji S, et al. A common polymorphism in the interleukin-8 gene promoter is associated with an increased risk for recurrent Clostridium difficile infection. Clin Infect Dis. 2010 Dec 15;51(12):1406–1410.
8. Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med. 2010 Jan 21;362(3):197–205.
9. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013 Jan 31;368(5):407–415.
10. Garey KW, Ghantoji SS, Shah DN, et al. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother. 2011 Dec;66(12):2850–2855.
11. Sheitoyan-Pesant C, Abou Chakra CN, Pépin J, et al. Clinical and healthcare burden of multiple recurrences of Clostridium difficile infection. Clin Infect Dis. 2016 Mar 01;62(5):574–580.
12. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults:2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010 May;31(5):431–455.
13. Cornely OA, Crook DW, Esposito R, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA:a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis. 2012 Apr;12(4):281–289.
14. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011 Feb 3;364(5):422–431.
15. Pham VP, Luce AM, Ruppelt SC, et al. Age-stratified treatment response rates in hospitalized patients with Clostridium difficile infection treated with metronidazole. Antimicrob Agents Chemother. 2015 Jul 20;59:6113–6116.
16. Musher DM, Aslam S, Logan N, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis. 2005 Jun 01;40(11):1586–1590.
17. Johnson S, Louie TJ, Gerding DN, et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection:results from two multinational, randomized, controlled trials. Clin Infect Dis. 2014 Aug;59(3):345–354.•• Largest study to date to demonstrate the global inferiority of metronidazole compared to oral vancomycin for the treatment of CDI.
18. Crook DW, Walker AS, Kean Y, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection:meta-analysis of pivotal randomized controlled trials. Clin Infect Dis. 2012 Aug;55(Suppl 2):S93–S103.
19. Shah DN, Chan FS, Kachru N, et al. A multi-center study of fidaxomicin use for Clostridium difficile infection. Springerplus. 2016;5(1):1224.
20. Shah DN, Aitken SL, Barragan LF, et al. Economic burden of primary compared with recurrent Clostridium difficile infection in hospitalized patients:a prospective cohort study. J Hosp Infect. 2016 Jul;93(3):286–289.• Study demonstrating doubling of hospitalization days and costs associated with recurrent CDI.
21. Aitken SL, Joseph TB, Shah DN, et al. Healthcare resource utilization for recurrent Clostridium difficile infection in a large university hospital in Houston, Texas. PLoS One. 2014;9(7):e102848.
22. Gallagher JC, Reilly JP, Navalkele B, et al. Clinical and economic benefits of fidaxomicin compared to vancomycin for Clostridium difficile infection. Antimicrob Agents Chemother. 2015 Nov;59(11):7007–7010.
23. Goldenberg SD, Brown S, Edwards L, et al. The impact of the introduction of fidaxomicin on the management of Clostridium difficile infection in seven NHS secondary care hospitals in England:a series of local service evaluations. Eur J Clin Microbiol Infect Dis. 2016 Feb;35(2):251–259.•• Multi-hospital study deminstrating that routine use of a narrow spectrum anti-C. difficile antibiotic can reduce re-admission due to CDI recurrence.
24. Michalska K, Karpiuk I, Król M, et al. Recent development of potent analogues of oxazolidinone antibacterial agents. Bioorg Med Chem. 2013 Feb 1;21(3):577–591.
25. Locher HH, Seiler P, Chen X, et al. In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections. Antimicrob Agents Chemother. 2014;58(2):892–900.
26. Baldoni D, Gutierrez M, Timmer W, et al. Cadazolid, a novel antibiotic with potent activity against Clostridium difficile:safety, tolerability and pharmacokinetics in healthy subjects following single and multiple oral doses. J Antimicrob Chemother. 2014 Mar;69(3):706–714.
27. Locher HH, Caspers P, Bruyère T, et al. Investigations of the mode of action and resistance development of cadazolid, a new antibiotic for treatment of Clostridium difficile infections. Antimicrob Agents Chemother. 2014;58(2):901–908.•• Laboratory investigations including mode of action of cadazolid.
28. Rashid M-U, Lozano HM, Weintraub A, et al. In vitro activity of cadazolid against Clostridium difficile strains isolated from primary and recurrent infections in Stockholm, Sweden. Anaerobe. 2013 Apr;20:32–35.
29. Rashid M-U, Dalhoff A, Weintraub A, et al. In vitro activity of MCB3681 against Clostridium difficile strains. Anaerobe. 2014 Aug;28:216–219.
30. Chilton CH, Crowther GS, Baines SD, et al. In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection. J Antimicrob Chemother. 2014 Mar;69(3):697–705.
31. Gerding DN, Hecht DW, Louie T, et al. Susceptibility of Clostridium difficile isolates from a phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection. J Antimicrob Chemother. 2016 Jan;71(1):213–219.
32. Hubschwerlen C, Specklin J-L. 5-Hydroxymethyl-oxazolidinin-2-one-derivatives and their use as antibacterials. US8124623 B2 Feb 28, 2012. 2012.
33. Baines SD, O’Connor R, Saxton K, et al. Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model. J Antimicrob Chemother. 2009 Mar;63(3):520–525.
34. Gehin M, Desnica B, Dingemanse J. Minimal systemic and high faecal exposure to cadazolid in patients with severe Clostridium difficile infection. Int J Antimicrob Agents. 2015 Nov;46(5):576–581.
35. Louie T, Nord CE, Talbot GH, et al. Multicenter, double-blind, randomized, phase 2 study evaluating the novel antibiotic cadazolid in patients with Clostridium difficile infection. Antimicrob Agents Chemother. 2015 Oct;59(10):6266–6273.•• Phase II study of cadazolid vs. vancomycin demonstrating reduced CDI recurrence in patients given cadazolid.
36. Knight-Connoni V, Mascio C, Chesnel L, et al. Discovery and development of surotomycin for the treatment of Clostridium difficile. J Ind Microbiol Biotechnol. 2016 Mar;43(2–3):195–204.
37. Boix V, Pesant T, Fegorak RN, et al. Primary clinical outcomes from a phase 3, randomized, double-blind, active-controlled study of surotomycin in patients with Clostridium difficile-associated diarrhoea. Presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2016; 2016; Amsterdam, Netherlands. Poster P0612.
38. U.S. National Institute of Health Clinicaltrials.gov website. [cited 2016 Sep 19]. Available from https://clinicaltrials.gov/ Keyword search cadazolid.
39. Chilton CH, Crowther GS, Todhunter SL, et al. Efficacy of surotomycin in an in vitro gut model of Clostridium difficile infection. J Antimicrob Chemother. 2014 Sep;69(9):2426–2433.
40. Koo HL, Van JN, Zhao M, et al. Real-time polymerase chain reaction detection of asymptomatic Clostridium difficile colonization and rising C. difficile-associated disease rates. Infect Control Hosp Epidemiol. 2014 Jun;35(6):667–673.• Study demonstrating that routine testig of CDI with polymerase chain reaction (PCR) testing may detect patients with asymptomatic colonization.